News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stem Cell Firm Regeneus Raising Targets $10 Million


8/19/2013 7:03:01 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REGENEUS executive chairman John Martin blanches at suggestions the regenerative medicine minnow is a poor man's alternative to stem-cell play Mesoblast, which commands a $1.9 billion market valuation. "We are not a poor man's anyone -- we have our own story," Mr Martin said, adding "There's no doubt Mesoblast has done a good job priming the Australian market about stem-cell therapies." In the first non-device biotech listing in more than two years, Regeneus principals are seeking to raise $10 million in an IPO, valuing the Sydney-based human and veterinary therapy outfit at $45m.

Help employers find you! Check out all the jobs and post your resume.

Read at The Australian

comments powered by Disqus
Regeneus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES